Logo image of RMED

RA MEDICAL SYSTEMS INC (RMED) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:RMED - US74933X3026 - Common Stock

0.594 USD
+0.05 (+10%)
Last: 8/17/2023, 8:04:01 PM
0.5785 USD
-0.02 (-2.61%)
After Hours: 8/17/2023, 8:04:01 PM
Fundamental Rating

3

RMED gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. While RMED seems to be doing ok healthwise, there are quite some concerns on its profitability. RMED is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year RMED has reported negative net income.
  • In the past year RMED has reported a negative cash flow from operations.
RMED Yearly Net Income VS EBIT VS OCF VS FCFRMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

  • The profitability ratios for RMED are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RMED Yearly ROA, ROE, ROICRMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 600 800 1K

1.3 Margins

  • With a Gross Margin value of 15.56%, RMED is not doing good in the industry: 82.91% of the companies in the same industry are doing better.
  • RMED does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RMED Yearly Profit, Operating, Gross MarginsRMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -50K -100K -150K

More info and screens

6

2. Health

2.1 Basic Checks

  • RMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RMED has more shares outstanding than it did 1 year ago.
  • RMED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RMED Yearly Shares OutstandingRMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
RMED Yearly Total Debt VS Total AssetsRMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -9.32, we must say that RMED is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of RMED (-9.32) is worse than 79.90% of its industry peers.
  • There is no outstanding debt for RMED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.32
ROIC/WACCN/A
WACC9.44%
RMED Yearly LT Debt VS Equity VS FCFRMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M

2.3 Liquidity

  • RMED has a Current Ratio of 2.86. This indicates that RMED is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.86, RMED is in line with its industry, outperforming 41.21% of the companies in the same industry.
  • A Quick Ratio of 2.85 indicates that RMED has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.85, RMED perfoms like the industry average, outperforming 53.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.85
RMED Yearly Current Assets VS Current LiabilitesRMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 73.38% over the past year.
  • RMED shows a strong growth in Revenue. In the last year, the Revenue has grown by 221.43%.
  • Measured over the past years, RMED shows a very negative growth in Revenue. The Revenue has been decreasing by -70.11% on average per year.
EPS 1Y (TTM)73.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.59%
Revenue 1Y (TTM)221.43%
Revenue growth 3Y-77.76%
Revenue growth 5Y-70.11%
Sales Q2Q%844.44%

3.2 Future

  • Based on estimates for the next years, RMED will show a very strong growth in Earnings Per Share. The EPS will grow by 26.23% on average per year.
  • Based on estimates for the next years, RMED will show a very strong growth in Revenue. The Revenue will grow by 1049.91% on average per year.
EPS Next Y52.85%
EPS Next 2Y40.99%
EPS Next 3Y26.23%
EPS Next 5YN/A
Revenue Next Year13964.3%
Revenue Next 2Y2408.98%
Revenue Next 3Y1049.91%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RMED Yearly Revenue VS EstimatesRMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
RMED Yearly EPS VS EstimatesRMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RMED. In the last year negative earnings were reported.
  • Also next year RMED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RMED Price Earnings VS Forward Price EarningsRMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RMED Per share dataRMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

  • RMED's earnings are expected to grow with 26.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.99%
EPS Next 3Y26.23%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for RMED!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RA MEDICAL SYSTEMS INC

NYSEARCA:RMED (8/17/2023, 8:04:01 PM)

After market: 0.5785 -0.02 (-2.61%)

0.594

+0.05 (+10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14
Earnings (Next)11-13
Inst Owners0%
Inst Owner Change0%
Ins Owners3.86%
Ins Owner Change0%
Market Cap4.16M
Revenue(TTM)90.00K
Net Income(TTM)-88.57M
Analysts85.71
Price Target7.14 (1102.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6987%
Min EPS beat(2)-6987%
Max EPS beat(2)-6987%
EPS beat(4)1
Avg EPS beat(4)-2335.29%
Min EPS beat(4)-6987%
Max EPS beat(4)46.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)19.05%
Min Revenue beat(2)19.05%
Max Revenue beat(2)19.05%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1042.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.25
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB 13.88
EV/EBITDA N/A
EPS(TTM)-45.97
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.72
OCFYN/A
SpS0.01
BVpS5.12
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.56%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.85
Altman-Z -9.32
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)7.97%
Cap/Depr(5y)26.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.59%
EPS Next Y52.85%
EPS Next 2Y40.99%
EPS Next 3Y26.23%
EPS Next 5YN/A
Revenue 1Y (TTM)221.43%
Revenue growth 3Y-77.76%
Revenue growth 5Y-70.11%
Sales Q2Q%844.44%
Revenue Next Year13964.3%
Revenue Next 2Y2408.98%
Revenue Next 3Y1049.91%
Revenue Next 5YN/A
EBIT growth 1Y0.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.2%
OCF growth 3YN/A
OCF growth 5YN/A

RA MEDICAL SYSTEMS INC / RMED FAQ

Can you provide the ChartMill fundamental rating for RA MEDICAL SYSTEMS INC?

ChartMill assigns a fundamental rating of 3 / 10 to RMED.


What is the valuation status for RMED stock?

ChartMill assigns a valuation rating of 1 / 10 to RA MEDICAL SYSTEMS INC (RMED). This can be considered as Overvalued.


How profitable is RA MEDICAL SYSTEMS INC (RMED) stock?

RA MEDICAL SYSTEMS INC (RMED) has a profitability rating of 0 / 10.


What is the expected EPS growth for RA MEDICAL SYSTEMS INC (RMED) stock?

The Earnings per Share (EPS) of RA MEDICAL SYSTEMS INC (RMED) is expected to grow by 52.85% in the next year.